XNCR - Xencor - Stock Price & Dividends

Xencor, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of engineered monoclonal antibody and cytokine therapeutics. These innovative treatments aim to improve the lives of patients suffering from cancer and autoimmune diseases.

The company's product portfolio includes Sotrovimab, a treatment that targets the SARS-CoV-2 virus, as well as Ultomiris and Monjuvi, which are used to treat patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and relapsed or refractory diffuse large B-cell lymphoma, respectively.

Xencor is also actively developing a range of promising pipeline products, including Plamotamab, a bispecific antibody in Phase I clinical trial for non-Hodgkin lymphoma, and Vudalimab, a bispecific antibody in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumor types. Additionally, the company is working on XmAb306, XmAb104, XmAb564, AMG 509, XmAb819, XmAb541, and XmAb662, which are all in various stages of clinical trials for the treatment of solid tumors, autoimmune diseases, and other conditions.

In collaboration with VIR Biotechnology, Xencor is co-developing VIR-3434 and VIR-2482, which are in Phase II clinical trials for the treatment of hepatitis B virus infection. Furthermore, the company is working on AIMab7195, Obexelimab, and Xpro1595, which are being developed to treat allergic diseases, autoimmune diseases, and Alzheimer's disease, respectively.

Xencor has established a license agreement with Caris Life Sciences, and the company was founded in 1997. Headquartered in Pasadena, California, Xencor is committed to pushing the boundaries of medical innovation to improve patient outcomes.